CEPHALON/TAP PROSTATE DISEASE DRUG DEVELOPMENT AGREEMENT
Executive Summary
CEPHALON/TAP PROSTATE DISEASE DRUG DEVELOPMENT AGREEMENT is based on the neuroscience firm's receptor tyrosine kinase (RTK) effector program. Under the agreement announced May 17, Takeda- Abbott Pharmaceuticals will provide Cephalon with $5 mil. in R&D payments for research conducted in 1994, with subsequent payments to be determined annually. TAP also will take an equity stake in Cephalon of $14.4 mil., representing the purchase of 1.2 mil. shares, or 6.8% of the company.